Evidence map›Paper›PMID 37592718›Full record

ArticleBritish journal of haematology2023

Histiocytic neoplasms: Going, going, but not quite gone.

Matthew Collin

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in British journal of haematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Matthew CollinInstitute of Translational and Clinical Research, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0001-6585-9586
Newcastle University · GB

Funding

Medical Research Council MR/Y008189/1
6 · The paper itself

Abstract

BRAF and MEK inhibitors have revolutionised the treatment of patients with high-risk histiocytic neoplasms but does a complete response mean that treatment can be withdrawn? Commentary on: Reiner et al. Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms. Br J Haematol 2023;203:389-394.

Indexed as

Hematologic NeoplasmsSkin NeoplasmsHumansMAP Kinase Signaling SystemProtein Kinase InhibitorsProto-Oncogene Proteins B-rafProtein Kinase InhibitorsProto-Oncogene Proteins B-rafhistiocytic neoplasmsMAP kinase inhibitor therapytargeted therapy

Identifiers

PMID37592718
OpenAlexW4385968546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.